New drug combo aims to outsmart brain Cancer's defenses

NCT ID NCT06831526

First seen Nov 01, 2025 · Last updated Jun 13, 2026 · Updated 28 times

Summary

This early study tests whether adding the drug azeliragon to standard chemoradiotherapy can help the immune system fight glioblastoma, an aggressive brain cancer. About 12 adults with newly diagnosed glioblastoma will receive either standard treatment or standard treatment plus azeliragon before a second surgery. Researchers will compare immune cells in tumor tissue to see if the combination reduces cancer-fighting suppression.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Washington University School of Medicine

    RECRUITING

    St Louis, Missouri, 63110, United States

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.